亚利桑那州

我们是谁

  • 4 月 5, 2022
    S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
  • 4 月 5, 2022
    Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer
  • 4 月 5, 2022
    An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.
  • 4 月 5, 2022
    KRAS G12C突变晚期结直肠癌患者MRTX849联合西妥昔单抗与化疗的3期研究（KRYSTAL-10）
  • 4 月 5, 2022
    IDE196对携带GNAQ/11突变或PRKC融合的实体瘤患者的研究
  • 4 月 5, 2022
    MRTX849 治疗 KRAS G12C 基因突变癌症患者的 1/2 期研究 KRYSTAL-1
  • 4 月 5, 2022
    A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer (BREAKWATER)
  • 4 月 5, 2022
    A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
  • 4 月 5, 2022
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
  • 4 月 5, 2022
    Study of TJ004309 in Combination With Atezolizumab (Tecentriq(R)) in Patients With Advanced or Metastatic Cancer